{
    "nct_id": "NCT04882917",
    "official_title": "A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)",
    "inclusion_criteria": "* Participants with advanced solid tumors, for whom no standard of care therapy exists or for whom is not considered sufficiently effective, or who cannot tolerate standard of care\n* Participants with Eastern Cooperative Oncology Group Performance status 0 or 1\n* Adequate hematological, hepatic, and renal function as defined in the protocol\n* Participants in Part 1B (the preliminary food effect assessment) must agree to provide paired tumor biopsies if not contraindicated for medical reasons\n* Other protocol defined inclusion criteria could apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant (i.e., active) uncontrolled intercurrent illness including, but not limited to:\n\n  1. Active infection (i.e., requiring systemic antibiotics or antifungals)\n  2. Uncontrolled arterial hypertension\n  3. Severe cardiac arrhythmia requiring medication\n  4. Cerebral vascular accident/stroke\n* Has known ataxia telangiectasia\n* Participants with tumors harboring previously identified ATM mutations\n* Participants with hypersensitivity to the active substance or to any of the excipients of M4076\n* Other protocol defined exclusion criteria could apply",
    "miscellaneous_criteria": ""
}